NCT02398461

An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse

A Double-Blind, Placebo-Controlled, Single Ascending Dose Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: Acorda Therapeutics · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 1, multi-center, double-blind, randomized, placebo-controlled, dose-escalation study in subjects with relapsing Multiple Sclerosis (MS). The primary outcome will be the safety and tolerability of a single dose of rHIgM22 in relapsing MS subjects.

Conditions

• Multiple Sclerosis, Acute Relapsing

Interventions

Type	Name	Description
DRUG	rHIgM22	Administered via IV infusion
DRUG	Placebo

Timeline

• Start date: 2015-04-01
• Primary completion: 2017-09-01
• Completion: 2017-09-21
• First posted: 2015-03-25
• Last updated: 2018-08-22

Locations

12 sites across 1 country: United States